FDA and CBD in 2026: Foods, Supplements, Drugs, and the Proposed New Pathway

Status verified July 12, 2026

CBD can appear in an oil, gummy, cosmetic, animal product, research material, or prescription drug. FDA does not regulate all of those products through one interchangeable rule.

The product category and intended use matter. So does the difference between current law and a proposed new framework.

As of July 12, 2026:

• FDA has approved one prescription drug containing purified CBD.
• FDA says it is unlawful under current federal law to add CBD to food or market CBD as a dietary supplement.
• FDA's 2023 call for a new pathway remains a policy recommendation, not an enacted pathway.
• A 2025 executive order directs research and work with Congress but does not approve consumer products.
• H.R. 7212 proposes a cannabinoid-hemp framework but remains introduced legislation.
• A separate enacted hemp-definition change is scheduled for November 12, 2026.

Those statements can all be true at the same time.

Read the source type before the headline

FDA policy develops through documents with different legal force.

Source	What it can show	What it does not automatically show
Enacted statute	Authority, definitions, duties, and effective dates passed by Congress	How every unresolved term will be implemented
Final regulation	Binding agency requirements within delegated authority	That every product complies
Guidance	FDA's current thinking and recommended approach	A new binding requirement by itself
Agency statement	Policy position, scientific assessment, or request to Congress	Enacted legislation
Warning letter	FDA's allegations and requested corrections for a named recipient	A court judgment applying to every seller
Introduced bill	Proposed statutory text and sponsor's approach	Current law
Executive order	Direction to executive officials within existing authority	An amendment to the FD&C Act by itself

Before repeating a CBD headline, identify which row it belongs in.

Hemp status does not remove FDA authority

The 2018 Farm Bill removed qualifying hemp from the Controlled Substances Act definition of marijuana, but it expressly preserved FDA's authority under the Federal Food, Drug, and Cosmetic Act and related laws.

That means “hemp-derived” is not an FDA product category or approval. A hemp ingredient used in a food still raises food-law questions. A product marketed to treat disease raises drug-law questions. A cosmetic, animal product, and prescription drug each have different regulatory paths.

The Controlled Substances Act and the FD&C Act answer different questions. Material can fall outside the CSA marijuana definition while still being unlawfully marketed for a particular FDA-regulated use.

FDA-approved CBD means one specific prescription drug

FDA has approved Epidiolex, a prescription cannabidiol oral solution, for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in specified patients.

That approval belongs to the drug, its formulation, manufacturing controls, approved labeling, indications, and conditions of use. It does not make every CBD product FDA-approved.

Do not transfer from Epidiolex to a consumer oil or gummy:

• disease-treatment claims;
• dosing;
• evidence of effectiveness;
• safety conclusions;
• interaction information as a substitute for professional advice; or
• manufacturing or purity assumptions.

An approved drug label is evidence for that approved drug. A retail product needs its own lawful category, labeling, specifications, and support.

CBD in foods

FDA's current public position is that it is unlawful to introduce food with added CBD into interstate commerce. The agency points to the FD&C Act's drug-exclusion provisions and its conclusion that CBD was not marketed in food before the relevant drug investigations or approval.

The existence of CBD foods in stores or online does not change the stated federal position. Marketplace presence is not the same as FDA authorization.

Food questions can also involve:

• food-additive status;
• generally recognized as safe conclusions;
• ingredient identity;
• manufacturing controls;
• contaminant limits;
• labeling and allergen requirements;
• claims; and
• state law.

The analysis is not resolved by a hemp COA or a delta-9 THC percentage alone.

CBD marketed as a dietary supplement

FDA says CBD and THC are excluded from the statutory dietary-supplement definition under the drug-exclusion provision, based on the evidence available to the agency. FDA says it has not seen evidence that CBD was marketed as a dietary supplement or conventional food before the relevant drug investigations began.

This point is often confused with the general rules for lawful dietary supplements. FDA does not ordinarily approve dietary supplements or their labels before sale. But that general fact does not establish that CBD qualifies as a dietary ingredient under current law.

A “Supplement Facts” panel or the word supplement on a package does not settle the category. Labels are claims; legal status comes from the governing statute, facts, and agency position.

CBD drug claims

A product's intended use can make it a drug. Claims to diagnose, cure, mitigate, treat, or prevent disease are central evidence of drug intended use.

Examples include explicit disease statements and implied claims created by product names, testimonials, imagery, directions, or comparisons to approved treatments. A disclaimer does not automatically neutralize the rest of the marketing.

FDA warning letters are allegations and agency compliance communications, not court judgments. They should be described by date, recipient, claims cited, and requested corrective action. Their value is showing how FDA applies its current position—not proving that every statement in a broader product category has been adjudicated.

Disease claims can also appear indirectly. A product page can create intended use through symptom headings, before-and-after stories, named medical conditions in testimonials, instructions that resemble treatment, or claims that a product can replace approved care.

Editorial articles should not become an indirect claims channel. A neutral explanation of a study, FDA action, or product label needs the population, material, dose, endpoint, limitations, and regulatory status; it should not end by attaching the result to a store product that was not studied.

IHF editorial content does not use product testimonials or disease-specific recommendations as substitutes for approved evidence.

Cosmetics are a different category

Cosmetics generally do not require FDA premarket approval, apart from color-additive requirements and certain other provisions. But they still may not be adulterated or misbranded.

A topical product can also become a drug based on intended-use claims. “Moisturizes skin” and “treats eczema” do not raise the same regulatory question.

The word topical therefore does not create a CBD safe harbor. Ingredients, safety substantiation, labeling, claims, and state rules still matter.

Animal foods and animal drugs

FDA says it has not approved CBD for use in animal food and has concerns about exposure through food-producing animals. Products marketed to diagnose, treat, or prevent animal disease can raise new-animal-drug requirements.

A human-product COA does not establish that an ingredient is lawful or appropriate for animal use. Animal species, food-chain exposure, intended use, labeling, and veterinary considerations are separate.

What FDA said in 2023

On January 26, 2023, FDA concluded that its existing food and dietary-supplement frameworks were not appropriate for CBD. The agency said a new regulatory pathway could include safeguards such as labeling, contaminant controls, CBD-content limits, minimum purchase age, and measures to reduce child ingestion.

That statement did two things:

1. It described FDA's assessment of safety and regulatory gaps.
2. It asked Congress to create a different pathway.

It did not create the pathway. FDA cannot turn a request for new statutory authority into enacted legislation by publishing a statement.

What the 2025 executive order changed

Executive Order 14370, signed December 18, 2025, directs federal work on medical-marijuana rescheduling, CBD research, and a possible hemp-derived-cannabinoid framework.

The order directs executive officials to work with Congress on updating the future final-product definition and considering elements such as per-serving limits, per-container limits, and CBD-to-THC ratios.

An executive order can direct executive-branch work within existing authority. It does not amend the FD&C Act, enact a new food or supplement category, or itself approve an IHF product.

The order is therefore executive direction, not an enacted consumer-CBD pathway.

H.R. 7212 remains a proposal

H.R. 7212 was introduced January 22, 2026. It would amend the FD&C Act to create a regulatory framework for cannabinoid hemp products.

As of July 12, Congress.gov lists the bill as introduced and referred to the House Committee on Energy and Commerce. It has not passed the House or Senate and has not been signed into law.

Its text can show what a sponsor proposes. It cannot be cited as the current rule for selling CBD foods, supplements, or other products.

The November 12 hemp change is separate

Public Law 119-37 is enacted and scheduled to change the federal hemp definition November 12, 2026. It adds product exclusions, a per-container threshold for certain final products, and directions for FDA to publish cannabinoid lists and clarify container-specific amounts.

That law changes which materials and products fit the federal hemp definition. It does not, by itself, replace FDA's separate FD&C Act analysis for foods, supplements, drugs, cosmetics, or animal products.

Section 781 directed FDA to publish specified cannabinoid lists within 90 days of enactment. IHF's July 12 review did not locate a clearly labeled FDA publication fulfilling those list directives. That is a source gap, not permission to invent the list or assume which cannabinoids FDA will include.

The enacted timeline and pending repeal/delay bills are tracked in Federal Hemp Law in 2026: What Changes on November 12.

What a COA can and cannot establish

A matched COA can document what a laboratory measured in a submitted sample. It can help verify cannabinoid results, units, batch identity, dates, and selected contaminant panels.

It cannot, by itself, establish:

• FDA approval;
• lawful food-additive status;
• dietary-supplement eligibility;
• disease-treatment effectiveness;
• compliant labeling and manufacturing;
• state legality; or
• that every unit matches the submitted sample.

Use How to Read a Hemp Certificate of Analysis for the laboratory-document questions. Keep the FDA product-category question separate.

A reader's status checklist

When evaluating a CBD claim, ask:

1. What product category is being claimed: food, supplement, drug, cosmetic, animal product, or something else?
2. What intended use appears in the label, website, testimonials, and directions?
3. Is the source current law, an FDA statement, guidance, warning letter, executive order, introduced bill, or enacted statute?
4. What is the event date and effective date?
5. Does the statement concern one approved drug or consumer CBD generally?
6. What does the batch COA actually establish?
7. What state rules also apply?

The phrase “FDA compliant” is not a useful shortcut unless the product category, claims, records, and specific requirements are identified.

What remains unresolved in 2026

The public debate is no longer only about whether FDA wants a different pathway. The unresolved questions include who would set and enforce content limits, which cannabinoid products would qualify, how labels and adverse-event reporting would work, how children and vulnerable populations would be protected, and how a new federal framework would interact with state programs.

H.R. 7212 offers one legislative proposal. Executive Order 14370 asks officials to work with Congress. Public Law 119-37 creates a separate hemp-definition deadline. None of those sources, standing alone, supplies a complete effective FDA pathway for mass-market CBD foods or supplements today.

Until an enacted and effective framework says otherwise, current FDA positions and existing law remain the relevant federal baseline. Future promises should be labeled as future proposals, with their status and dates attached.

Sources

• FDA: Regulation of Cannabis and Cannabis-Derived Products
• FDA consumer update on CBD products
• FDA's January 26, 2023 CBD pathway statement
• FDA-approved Epidiolex prescribing information
• Executive Order 14370
• Congress.gov: H.R. 7212 actions
• Public Law 119-37

This article provides general educational information, not legal or medical advice. FDA positions, legislation, product categories, and laws can change.